Mazdutide Research & Studies
We track 20 published, PubMed-indexed studies for Mazdutide, spanning 2022 to 2026. The research below includes 6 meta-analysiss, 6 clinical trials, 8 reviews.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
6
Meta-Analysiss
6
Clinical Trials
8
Reviews
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Meta-AnalysisAbulehia A, Ayesh H, et al.|Endocrinol Diabetes Metab|2026
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
Clinical TrialLuo Y, Jiang H, et al.|Contemp Clin Trials|2026
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
ReviewSon JW, le Roux CW, et al.|Endocr Rev|2026
Obesity in China: current progress and future prospects.
ReviewPan XF, Fang ZZ, et al.|Lancet Diabetes Endocrinol|2026
Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
ReviewAzam MH, Azam MH, et al.|Diabetes Obes Metab|2026
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
Meta-AnalysisLiu S, Hu J, et al.|Front Endocrinol (Lausanne)|2025
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
Clinical TrialJi L, Jiang H, et al.|N Engl J Med|2025
Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.
Clinical TrialBhattachar SN, Tham LS, et al.|Diabetes Obes Metab|2025
Mazdutide: First Approval.
ReviewShirley M|Drugs|2025
Emerging pharmacotherapies for obesity: A systematic review.
ReviewKokkorakis M, Chakhtoura M, et al.|Pharmacol Rev|2025
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.
ReviewBailey CJ, Flatt PR, Conlon JM|Peptides|2025
Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.
Meta-AnalysisAyesh H, Ayesh S, Niswender K|Am J Ther|2024
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
Meta-AnalysisNalisa DL, Cuboia N, et al.|Front Endocrinol (Lausanne)|2024
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Meta-AnalysisXie Z, Zheng G, et al.|Metabolism|2024
Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.
Meta-AnalysisDeng B, Ruan T, et al.|Endocrine|2024
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Clinical TrialZhang B, Cheng Z, et al.|Diabetes Care|2024
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
ReviewGogineni P, Melson E, et al.|Expert Opin Pharmacother|2024
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.
ReviewSidrak WR, Kalra S, Kalhan A|Indian J Endocrinol Metab|2024
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
Clinical TrialJi L, Jiang H, et al.|Nat Commun|2023
A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
Clinical TrialJiang H, Pang S, et al.|Nat Commun|2022